RESUMO
To provide the ancient literary evidence support for the clinical application and development of classical prescription based on systematical collection and analysis of the ancient Chinese medical literature containing Jinshui Liujun Jian, including its origin and development. Bibliometric analysis was used and information of Jinshui Liujun Jian in ancient Chinese medical literature was then collected for statistical analysis of formula compositions, main indications, dosage, preparation methods, etc. A total of 151 valid items of data were obtained from 48 ancient Chinese medicine books. Jinshui Liujun Jian was first recorded in Jingyue Quanshu written by ZHANG Jiebin. This prescription consisted of Rehmanniae Radix Praeparata, Angelicae Sinensis Radix, Pinelliae Rhizome, Citri Reticulatae Pericarpium, Poria and Glycyrrhizae Radix et Rhizome Praeparata cum Melle, and it was mainly used to treat the deficiency of lung and kidney, edema and excess production of phlegm, or Yin deficiency in the old, insufficient blood-qi, wind-cold evil, cough and disgusting, asthma and excessive phlegm. Doctors in later dynasties mostly followed the prescription compositions, dosages and indications in Jingyue Quanshu, and extended the clinical application of this prescription.
Assuntos
Medicamentos de Ervas Chinesas , Medicina Tradicional Chinesa , Prescrições , RizomaRESUMO
Objective: To investigate the variation in pharmacokinetics of berberine in the brain tissue of rats under the conditions of compound compatibility with geniposide and baicalin or the primary formula HuanglianJiedu Decoction (HJD). Methods: The rats were divided into three groups including berberine group (247.39 mg/kg), compound combination group (berberine, geniposide, and baicalin of 247.39, 130.11, and 113.01 mg/kg) and HJD group (HJD 3.92 g/kg and berberine 247.39 mg/kg). After ig administration of those compounds or formula, the brain tissues of rats were collected immediately at 0.083, 0.25, 0.5, 1, 2, 4, 6, 8, 12, and 24 h respectively. The brain tissue was taken from the six rats in each group. A sensitive UPLC-MS method was developed for determining the concentration of berberine in the brain tissue of rats. The concentration-time curve was plotted and the pharmacokinetic parameters of rats in each group were calculated by DAS 2.0 software. Results: These results showed that the Cmax (368.59 ng/g) of berberine in rats with compound combination was increased compared with those with berberine alone (Cmax 108.01 ng/g), which is pronouncedly larger than the Cmax (31.97 ng/g) of berberine in the HJD group. Meanwhile, the AUC0-∞ of berberine in the compound combination group was 3 236.60 min∙ng/g which was much greater than the AUC0-∞ in rat brain with berberine (2 701.37 min∙ng/g) or HJD (420.34 min∙ng/g). Conclusion: The combination of geniposide and baicalin could promote the concentration of berberine, while the primary formula HJD could decrease the distribution of berberine in the brain tissue of rats.